Biomedical Science Letters

eISSN 2288-7415

Table. 2.

Susceptibility profiles of 29 CNAB and 5 CSAB isolates

Drug MIC range (μg/mL) MIC50 (μg/mL) MIC90 (μg/mL) No. (%) of susceptible isolates
CNAB (n=29) CSAB (n=5) CNAB (n=29) CSAB (n=5) CNAB (n=29) CSAB (n=5) All isolates (n=34) CNAB (n=29) CSAB (n=5)
Meropenem 16~128 0.5~4 128 1 256 4 5 0 (0) 5 (100)
Imipenem 32~256 1~4 128 2 256 4 5 0 (0) 5 (100)
Ceftazidime 32~≥1,024 32~512 128 128 512 128 0
Cefepime 32~256 32~256 128 64 256 128 0
Cefotaxime 16~128 16~64 64 32 128 64 0
Ampicillin/
sulbactam 16~256 16~64 64 32 128 64 4 1 (3.4) 3 (60)
Minocycline 1~32 0.5~4 16 2 32 1 32 27 (93.1) 5 (100)
Gentamicin 16~≥1,024 2~64 128 16 512 64 2 0 2 (40)
Ciprofloxacin 4~128 4~64 64 32 128 64 0
Tigecycline 0.5~32 0.5~4 8 1 16 4 12 8 (27.5) 4 (80)
Piperacillin 128~≥1,024 16~≥1,024 512 512 ≥1,024 ≥1,024 2 0 2 (100)
Colistin 0.5~4 0.5~1 1 1 1 1 28 23 (79.3) 5 (100)
Biomed Sci Letters 2021;27:59-68 https://doi.org/10.15616/BSL.2021.27.2.59
© 2021 Biomed Sci Letters